Valirx (VAL)

 

VAL Share PerformanceMore

52 week high7.7100 20/12/17
52 week low0.9000 15/11/17
52 week change -1.3711 (-28.87%)
4 week volume129,430,137 27/01/18
price3.3789
price date1519316012
close3.5000

Media for (VAL)

Presenter: Dr George Morris
06/02/2018
Presenter: Suzanne Dilly
16/01/2018

Latest NewsMore

Issue of options and directors dealings

RNS Number: 4699E ValiRx PLC 09 February 2018 VALIRX PLC ("ValiRx", the "Company" or the "Group") Issue of options and directors dealings London, UK ., 9 February 2018: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company , announces it has awarded options to directors and key management. The options may be exercised at a price of 4 pence...

ValiRx - Company Update

Holding(s) in Company

RNS Number: 8336D ValiRx PLC 02 February 2018 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: ValiRx PLC 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK...

Holding(s) in Company

RNS Number: 9452C ValiRx PLC 25 January 2018 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: ValiRx PLC 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK...

Holding(s) in Company

RNS Number: 7057C ValiRx PLC 23 January 2018 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: ValiRx PLC 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK...

Valirx to present on 13 February 2018 at the Shares and AJ Bell Spotlight Evening in London

If you are looking for some new investment ideas for 2018, then come along the Shares and AJ Bell Investor Evening in Lo...

ValiRx welcomes positive clinical results

ValiRx has provided an update on the clinical progress of an anti-cancer compound developed by ValiSeek, a joint venture...

ValiSeek Clinical Update (VAL401)

RNS Number: 9423B ValiRx PLC 16 January 2018 VALIRX PLC ("ValiRx", the "Company" or the "Group") VALISEEK CLINICAL UPDATE (VAL401) "Positive Impact of Patient Quality of Life and Immune Competency in VAL401 Phase II Clinical Trial" London, UK ., 16 January 2018: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company , is pleased...

Fundamental DataMore

EPS-8.54
Dividend yield0 %

Latest discussion posts More

Users' HoldingsMore

Users who hold Valirx also hold..

Codes & Symbols

ISINGB00BWWYSP41
SymbolsVAL, LSE:VAL, VAL.L, VAL:LN, LON:VAL, XLON:VAL

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account